Neurocrine Biosciences (NBIX) Other Accumulated Expenses (2011 - 2026)

Neurocrine Biosciences has reported Other Accumulated Expenses for 15 years, with the latest figure at $58.7 million in Q1 2026.

• For the quarter ending Q1 2026, Other Accumulated Expenses rose 23.06% year-over-year to $58.7 million; the trailing twelve-month figure through Mar 2026 stood at $58.7 million (up 23.06% YoY), and the FY2025 full-year result was $69.1 million, up 49.89% from the prior year.
• Other Accumulated Expenses for Q1 2026 stood at $58.7 million, down from $69.1 million in the prior quarter.
• The five-year high for Other Accumulated Expenses was $69.1 million in Q4 2025, with the low at $17.6 million in Q1 2022.
• Historically, Other Accumulated Expenses has averaged $36.3 million across 5 years, with a median of $36.7 million in 2024.
• Annual changes were most pronounced in 2022 — Other Accumulated Expenses decreased 9.5% — and 2024, when it soared 99.46%.
• Neurocrine Biosciences' Other Accumulated Expenses stood at $20.7 million in 2022, then surged by 73.43% to $35.9 million in 2023, then advanced by 28.41% to $46.1 million in 2024, then jumped by 49.89% to $69.1 million in 2025, then dropped by 15.05% to $58.7 million in 2026.
• The last three Other Accumulated Expenses figures came in at $58.7 million (Q1 2026), $69.1 million (Q4 2025), and $53.7 million (Q3 2025), per Business Quant data.